Sooner Clinical Research | Oklahoma City, OK

Research site

(Unclaimed)

Location

5929 N. May Avenue, Suite 401, Oklahoma City, Oklahoma, United States of America

Site insights

Top conditions

Top treatments

Cariprazine

Pregabalin

Rapastinel

ABBV-932

Dapagliflozin

SEP-4199

Balsalazide Disodium

BMS-512148

Aticaprant

Lyrica

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 65 total trials

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of...

Enrolling

Major Depressive Disorder

Drug: Azetukalner

Drug: Placebo

A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United S...

Enrolling

Bipolar II Disorder

Bipolar I Disorder

Drug: Icalcaprant

Drug: Placebo for Icalcaprant

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. (3112 Ped BPD)

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United S...

Enrolling

Bipolar I Disorder

Depression

Drug: Placebo

Drug: Cariprazine

A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

Major depressive disorder (MDD; depression) is a mood disorder that causes a continued feeling of sadness and loss of interest. It is a common and se...

Enrolling

Major Depressive Disorder

Drug: Icalcaprant

Drug: Placebo for Icalcaprant

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately t...

Enrolling

Generalized Anxiety Disorder (GAD)

Drug: Antidepressant Therapy (ADT)

Drug: ABBV-932

Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. The purpose of this study is t...

Enrolling

Bipolar I or II Disorder

Drug: ABBV-932

Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder (GATE-251)

The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel....

Enrolling

Major Depressive Disorder

Drug: Zelquistinel